The successful treatment of cancer with inhibition of the CTLA-4, PD-1, PD-L1, and CD80/86 pathways in adults was the basis for our exploration into additional checkpoint molecule expression in neuroblastoma. This evidence concerns the gene CD80 and neuroblastoma.